KalVista Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	May '26 May 22, 2026	Dec '25 Dec 31, 2025	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Market Cap	1,426	822	685	483	291	313
Market Cap Growth	135.37%	19.97%	41.98%	65.58%	-6.74%	-48.75%
Enterprise Value	1,426	671.79	468.94	278.24	149.25	153.54
Last Close Price	26.79	16.15	13.77	11.35	8.53	12.73
PS Ratio	12.46	16.75	-	-	-	-
PB Ratio	-	-303.23	7.18	2.34	1.81	1.69
P/TBV Ratio	-73.21	-303.23	7.17	2.02	1.48	1.68
EV/Sales Ratio	12.45	13.69	-	-	-	-
Debt / Equity Ratio	-7.62	-55.31	0.05	0.03	0.04	0.04
Net Debt / Equity Ratio	6.80	54.83	-2.25	-0.98	-0.88	-0.85
Net Debt / EBITDA Ratio	0.76	1.33	1.15	1.45	1.28	1.65
Net Debt / FCF Ratio	0.86	-	1.40	2.28	1.85	2.00
Asset Turnover	-	0.17	0	0	0	0
Inventory Turnover	-	1.80	-	-	-	-
Quick Ratio	4.97	5.39	4.92	9.60	11.04	15.58
Current Ratio	5.17	5.58	5.35	9.90	11.46	16.73
Return on Equity (ROE)	1640.50%	-107.44%	-121.50%	-68.90%	-53.69%	-37.23%
Return on Assets (ROA)	-55.25%	-38.89%	-78.79%	-67.10%	-57.29%	-40.60%
Return on Invested Capital (ROIC)	7079.38%	6331.44%	-26219.90%	-1201.41%	-472.18%	-468.40%
Return on Capital Employed (ROCE)	-65.00%	-45.67%	-89.91%	-73.77%	-61.51%	-42.51%
Buyback Yield / Dilution	-9.26%	-2.51%	-34.98%	-31.90%	-13.97%	-28.17%
Total Shareholder Return	-9.26%	-2.51%	-34.98%	-31.90%	-13.97%	-28.17%

Updated May 14, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q